We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Ahead of Genentech to File BLA for CLL Drug
GSK Ahead of Genentech to File BLA for CLL Drug
February 6, 2009
GlaxoSmithKline (GSK) and Genmab have submitted a BLA for their investigational anti-CD20 antibody Arzerra to treat chronic lymphocytic leukemia (CLL) at least five months before Genentech plans to file an application for Rituxan to treat CLL.